Haroon · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2014 · prospective non-randomized controlled cohort study · n=31

IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy.

Cited 155 times in the scientific literature.

Level 3 - non-randomized controlled study

Non-randomized controlled cohort study

PubMed 24481242 · doi:10.1038/npp.2014.25 · record verified 2026-08-30

What was done

Single-voxel magnetic resonance spectroscopy (MRS) was used to measure glutamate concentrations normalized to creatine (Glu/Cr) in the dorsal anterior cingulate cortex (dACC) and basal ganglia in 31 patients with hepatitis C. Patients were evaluated before and after approximately 1 month of either no treatment (n = 14) or treatment with IFN-alpha (n = 17). Depressive symptoms and fatigue were measured using the Inventory of Depressive Symptoms-Clinician Rating (IDS-C) and the Multidimensional Fatigue Inventory.

What was found

IFN-alpha was associated with a significant increase in Glu/Cr in the dACC and left basal ganglia, with no changes found in the right basal ganglia (the abstract reports no exact numerical values, effect sizes, or p-values). Increases in dACC Glu/Cr positively correlated with IDS-C scores across the entire group, but not in either group individually. Glu/Cr increases in the left basal ganglia correlated with decreased motivation across the whole sample and within the IFN-alpha group alone. No significant correlations were found between Glu/Cr and inflammatory markers.

Why it matters

This study provides human in vivo evidence that systemic inflammatory cytokines like IFN-alpha can elevate glutamate levels in specific corticolimbic regions, suggesting a neurochemical pathway connecting inflammation to depression and reduced motivation.

Limits

The study had a small sample size (n = 31), non-randomized allocation, and lacked reporting of exact numerical values or confidence intervals in the abstract. The correlation between dACC glutamate and depressive symptoms was not significant within the treatment cohort alone.

Cited by